{"id":214945,"date":"2025-05-28T17:05:40","date_gmt":"2025-05-28T22:05:40","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/05\/new-biomarker-may-guide-best-use-of-kras-inhibitors-in-lung-cancer"},"modified":"2025-05-28T17:05:40","modified_gmt":"2025-05-28T22:05:40","slug":"new-biomarker-may-guide-best-use-of-kras-inhibitors-in-lung-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/05\/new-biomarker-may-guide-best-use-of-kras-inhibitors-in-lung-cancer","title":{"rendered":"New biomarker may guide best use of KRAS inhibitors in lung cancer"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/new-biomarker-may-guide-best-use-of-kras-inhibitors-in-lung-cancer.jpg\"><\/a><\/p>\n<p>Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), following treatment with the KRAS targeted therapy sotorasib.<\/p>\n<p>Results from the study, published in <a href=\"https:\/\/www.nature.com\/articles\/s41591-025-03732-5\" target=\"_blank\"><i>Nature Medicine<\/i><\/a>, found patients with <a href=\"https:\/\/medicalxpress.com\/tags\/lung+tumors\/\" rel=\"tag\" class=\"\">lung tumors<\/a> that express low TTF-1 levels responded poorly to sotorasib\u2014with a median progression free survival (PFS) of 2.8 months and a <a href=\"https:\/\/medicalxpress.com\/tags\/median+overall+survival\/\" rel=\"tag\" class=\"\">median overall survival<\/a> (OS) of 4.5 months\u2014whereas patients with tumors expressing high TTF-1 levels had a median PFS of 8.1 months and a median OS of 16 months.<\/p>\n<p>\u201cSince TTF-1 testing is routinely performed in lung cancer diagnosis, it gives physicians an immediate tool to help identify those patients who may benefit from sotorasib and those who may need an alternative or intensified treatment approach,\u201d said lead author Ferdinandos Skoulidis, M.D., Ph.D., associate professor of Thoracic\/Head and Neck Medical Oncology.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), following treatment with the KRAS targeted therapy sotorasib. Results from the study, published in Nature Medicine, found patients with lung tumors that [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-214945","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/214945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=214945"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/214945\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=214945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=214945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=214945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}